TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models
R Guiho, K Biteau, G Grisendi, J Taurelle… - … Journal of Cancer, 2016 - Wiley Online Library
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS
patients have not seen any major therapeutic progress in the last 30 years, in particular in
the case of metastatic disease, which requires new therapeutic strategies. The pro‐apoptotic
cytokine TNF‐Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells
while sparing normal cells, making it a promising therapeutic tool in several types of cancer.
However, certain EWS cell lines appear resistant to recombinant human (rh) TRAIL‐induced …
patients have not seen any major therapeutic progress in the last 30 years, in particular in
the case of metastatic disease, which requires new therapeutic strategies. The pro‐apoptotic
cytokine TNF‐Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells
while sparing normal cells, making it a promising therapeutic tool in several types of cancer.
However, certain EWS cell lines appear resistant to recombinant human (rh) TRAIL‐induced …
[PDF][PDF] TRAIL Delivered by Mesenchymal Stromal/Stem Cells Counteracts Tumor Development in Orthotopic Ewing Sarcoma Models
M GANTIER, D HEYMANN, M DOMINICI, F REDINI - 2017 - core.ac.uk
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS
patients have not seen any major therapeutic progress in the last thirty years, in particular in
the case of metastatic disease, which requires new therapeutic strategies. The pro-apoptotic
cytokine TNF-Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells
while sparing normal cells, making it a promising therapeutic tool in several types of cancer.
However, certain EWS cell lines appear resistant to recombinant human (rh) TRAIL-induced …
patients have not seen any major therapeutic progress in the last thirty years, in particular in
the case of metastatic disease, which requires new therapeutic strategies. The pro-apoptotic
cytokine TNF-Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells
while sparing normal cells, making it a promising therapeutic tool in several types of cancer.
However, certain EWS cell lines appear resistant to recombinant human (rh) TRAIL-induced …
以上显示的是最相近的搜索结果。 查看全部搜索结果